Sky Labs
Venture Round in 2020
Sky Labs is a technology company focused on developing innovative wearable devices for health monitoring, particularly a cuffless ring-type blood pressure monitor and a device known as the Cardio Tracker (CART). The CART is designed for continuous monitoring of atrial fibrillation, a common and often undiagnosed heart condition affecting many individuals over 40. This device can be worn comfortably on any finger and is both waterproof and dustproof, allowing users to wear it throughout their daily activities without interruption. It operates without user intervention, automatically detecting and recording atrial fibrillation, which users can track via a smartphone application. The device aims not only to assist individuals in managing their heart health but also to provide valuable data to healthcare professionals for accurate diagnosis. Sky Labs is currently conducting clinical trials in collaboration with Seoul National University Hospital to validate the performance of its technology, with an initial focus on the atrial fibrillation patient market in Finland, and an extended target market of millions worldwide. The company is also partnering with Bayer to explore further healthcare innovations.
# Nodit
Nodit is a Web3 development platform specialized in blockchain data. Nodit aims to provide enterprise-grade multi-chain Web3 infrastructure accessible to everyone. By offering reliable node infrastructure with 99.9% uptime and consistent ready-to-query blockchain data at an affordable price, we are facilitating developers’ entry into the Web3 world.
# Lambda256
Lambda256, the blockchain tech arm of Dunamu, developed and operates Nodit, which enhances efficiency in managing tasks like blockchain network setup, node operation, and data processing for Ethereum, Arbitrum, and Aptos and Luniverse, a cloud-based blockchain infrastructure platform. Lambda256 also offers a travel rule solution to meet FATF guidelines, improving security and compliance for virtual asset transactions. The company secured Series A funding, followed by Series B funding in December 2021, achieving a total accumulated investment of approximately +80 million USD.
BIORCHESTRA
Venture Round in 2019
BIORCHESTRA is a biotech company that develops RNA-based therapeutics for treating neuroinflammatory diseases. They focus on changing the therapeutic paradigm from treating the symptoms to providing a fundamental cure for diseases. BIORCHESTRA develops neuroinflammatory disease therapeutics, with a particular emphasis on comprehensive patient care. BIORCHESTRA's complementary discovery platforms range from diagnosis to treatment monitoring.
G+FLAS Life Sciences
Series C in 2019
G+FLAS Life Sciences is an agricultural biotechnology company focused on genome editing technologies for crops and health-related applications. It develops glycoengineered plants using CRISPR-PLUS to selectively remove glycosylation-related genes and provides gene-editing delivery methods into plant protoplasts. The company also pursues development of novel seeds and gene therapy drugs based on CRISPR-Cas, and operates plant cultivation facilities to support pharmaceutical and anticancer R&D. In addition to crop improvements, G+FLAS has explored nutritionally enhanced foods, including vitamin D3-enriched tomatoes, and has pursued strategic partnerships to scale commercialization, such as collaborations with large industry players to enable broader adoption of its technology. Through its integrated approach spanning plant biotechnology and therapeutic research, G+FLAS Life Sciences aims to advance sustainable agriculture and novel drug development.
BiomX Inc. is a clinical-stage company based in Ness Ziona, Israel, focused on developing bacteriophage-based therapies aimed at treating and preventing diseases linked to microbiome imbalances. The company’s innovative approach targets harmful bacteria associated with various conditions, including skin issues and chronic diseases such as inflammatory bowel disease, colorectal cancer, and primary sclerosing cholangitis. Its lead product candidates include BX001, aimed at improving skin appearance, and BX002, a therapeutic phage for inflammatory bowel disease. Additional candidates such as BX003 and BX004 target bacteria associated with liver disorders and chronic pulmonary infections, respectively. BiomX collaborates with esteemed institutions, including the Weizmann Institute of Science and MIT, to leverage cutting-edge research in microbiome modulation. Founded in 2015, BiomX is dedicated to advancing microbiome therapeutics through its robust development pipeline.